Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia

Xiaoxiao Lu,1 Bruno Emond,2 Laura Morrison,2 Frederic Kinkead,2 Patrick Lefebvre,2 Marie-Hélène Lafeuille,2 Wasiulla Khan,1 Linda H Wu,1 Zaina P Qureshi,1 Ryan Jacobs3 1Real World Value and Evidence, Oncology, Janssen Scientific Affairs, LLC, Horsham, PA, USA; 2Health Economics and Outcomes Research...

Full description

Bibliographic Details
Main Authors: Lu X, Emond B, Morrison L, Kinkead F, Lefebvre P, Lafeuille MH, Khan W, Wu LH, Qureshi ZP, Jacobs R
Format: Article
Language:English
Published: Dove Medical Press 2023-08-01
Series:Patient Preference and Adherence
Subjects:
cll/sll
bruton’s tyrosine kinase inhibitor
treatment compliance
proportion of days covered
medication possession ratio
Online Access:https://www.dovepress.com/real-world-comparison-of-first-line-treatment-adherence-between-single-peer-reviewed-fulltext-article-PPA

Internet

https://www.dovepress.com/real-world-comparison-of-first-line-treatment-adherence-between-single-peer-reviewed-fulltext-article-PPA

Similar Items